176 related articles for article (PubMed ID: 35604149)
1. An Experimental Adult Zebrafish Model for
Howlader DR; Bhaumik U; Halder P; Satpathy A; Sarkar S; Ghoshal M; Maiti S; Withey JH; Mitobe J; Dutta S; Koley H
Microbiol Spectr; 2022 Jun; 10(3):e0034722. PubMed ID: 35604149
[TBL] [Abstract][Full Text] [Related]
2. Ascorbate deficiency increases progression of shigellosis in guinea pigs and mice infection models.
Skerniskyte J; Mulet C; André AC; Anderson MC; Injarabian L; Buck A; Prade VM; Sansonetti PJ; Reibel-Foisset S; Walch AK; Lebel M; Lykkesfeldt J; Marteyn BS
Gut Microbes; 2023 Dec; 15(2):2271597. PubMed ID: 37876025
[No Abstract] [Full Text] [Related]
3.
Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
[No Abstract] [Full Text] [Related]
4. Use of zebrafish to study
Duggan GM; Mostowy S
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590642
[No Abstract] [Full Text] [Related]
5.
Willis AR; Torraca V; Gomes MC; Shelley J; Mazon-Moya M; Filloux A; Lo Celso C; Mostowy S
mBio; 2018 Jun; 9(3):. PubMed ID: 29946048
[TBL] [Abstract][Full Text] [Related]
6. Shigellosis.
Niyogi SK
J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
[TBL] [Abstract][Full Text] [Related]
7. Shigellosis: the current status of vaccine development.
Kweon MN
Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
[TBL] [Abstract][Full Text] [Related]
8. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer AM; Kaminski RW; Porter CK; Chakraborty S; Clarkson KA; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts H; Feijoo BL; Halpern J; Sack D; Riddle MS; Fonck VG
EBioMedicine; 2021 Apr; 66():103310. PubMed ID: 33862589
[TBL] [Abstract][Full Text] [Related]
9. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis.
Chakrabarti MK; Bhattacharya J; Bhattacharya MK; Nair GB; Bhattacharya SK; Mahalanabis D
Acta Paediatr; 1999 Feb; 88(2):161-5. PubMed ID: 10102148
[TBL] [Abstract][Full Text] [Related]
10. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
Clarkson KA; Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer A; Porter CK; Chakraborty S; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts HP; Feijoo B; Halpern J; Sack D; Riddle MS; Fonck VG; Kaminski RW
EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model.
Barman S; Koley H; Ramamurthy T; Chakrabarti MK; Shinoda S; Nair GB; Takeda Y
Microbiol Immunol; 2013 Nov; 57(11):762-71. PubMed ID: 24033533
[TBL] [Abstract][Full Text] [Related]
12. An automated microscopy workflow to study Shigella-neutrophil interactions and antibiotic efficacy in vivo.
Lensen A; Gomes MC; López-Jiménez AT; Mostowy S
Dis Model Mech; 2023 Jun; 16(6):. PubMed ID: 37161932
[TBL] [Abstract][Full Text] [Related]
13. New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies.
Shim DH; Suzuki T; Chang SY; Park SM; Sansonetti PJ; Sasakawa C; Kweon MN
J Immunol; 2007 Feb; 178(4):2476-82. PubMed ID: 17277155
[TBL] [Abstract][Full Text] [Related]
14. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
mSphere; 2018; 3(2):. PubMed ID: 29600284
[TBL] [Abstract][Full Text] [Related]
15. Development of a new guinea-pig model of shigellosis.
Barman S; Saha DR; Ramamurthy T; Koley H
FEMS Immunol Med Microbiol; 2011 Aug; 62(3):304-14. PubMed ID: 21539623
[TBL] [Abstract][Full Text] [Related]
16. Shigella Pathogenesis Modeling with Tissue Culture Assays.
Koestler BJ; Ward CM; Payne SM
Curr Protoc Microbiol; 2018 Aug; 50(1):e57. PubMed ID: 29927109
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
Heine SJ; Diaz-McNair J; Martinez-Becerra FJ; Choudhari SP; Clements JD; Picking WL; Pasetti MF
Vaccine; 2013 Jun; 31(28):2919-29. PubMed ID: 23644075
[TBL] [Abstract][Full Text] [Related]
18. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella.
Felegary A; Nazarian S; Kordbacheh E; Fathi J; Minae ME
Int Immunopharmacol; 2021 Nov; 100():108132. PubMed ID: 34508943
[TBL] [Abstract][Full Text] [Related]
19. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
Yagnik B; Sharma D; Padh H; Desai P
Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673
[TBL] [Abstract][Full Text] [Related]
20. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
